Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study

NCT00947856 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00947856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00947856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2009
Completion date
March 31, 2013
Enrollment
110 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

disease, hodgkin, lymphoma, large-cell, anaplastic, lymphoma, non-hodgkin